局部晚期胃癌围手术期免疫治疗研究进展

摘 要：胃癌是我国主要癌种之一，胃癌根治术是患者治愈的唯一机会，但只有50%～60%的初始诊断胃癌患者适合胃癌根治术，尤其是局部晚期以及晚期患者往往失去手术机会。MAGIC及ACCORD07/FFCD9703的研究结果明确了以氟尿嘧啶为主的联合化疗方案作为局部晚期胃癌围手术期治疗标准的地位。然而，胃癌患者的5年总生存率仍较低。免疫治疗在晚期胃癌一线治疗中疗效显著，同时，免疫检查点抑制剂、肿瘤疫苗、细胞疗法等免疫疗法在胃癌局部晚期患者围手术期治疗中也展现出了一定的安全性和有效性。全文就免疫治疗在局部晚期胃癌围手术期治疗中的研究进展进行综述。

Research Progress of Perioperative Immunotherapy for Locally Advanced Gastric Cancer

Abstract： Gastric cancer is one of the major malignant tumors in China， and radical surgery is the only chance for patients to be cured， however， only 50%～60% of patients are suitable for radical surgery， for the patients with locally advanced and advanced stages often lose the chance of surgery. The results of the MAGIC and ACCORD07/FFCD9703 studies confirmed fluorouracil-based combination chemotherapy regimens as the standard of perioperative treatment for locally advanced gastric cancer； however， the 5-year overall survival of gastric cancer patients is still relatively low. Immunotherapy， including immune checkpoint inhibitors， tumor vaccines and cellular therapy， has shown significant efficacy in the first-line treatment of advanced gastric cancer， and also demonstrated safety and efficacy in the perioperative treatment of patients with locally advanced gastric cancer. This paper reviews the research progress of immunotherapy in the perioperative treatment of locally advanced gastric cancer.